NCT07316439Active, not recruiting
Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer
Clinical Outcomes of ER-Positive to Negative Conversion Versus Triple-Negative Breast Cancer (TNBC): Evidence From a 18F-fluoroestradiol Positron Emission Tomography/Computed Tomography (18F-FES PET/CT) Guided Propensity-Score-Matched Study
Source: ClinicalTrials.gov · Last updated 5 Jan 2026
Brief summary (registry, in English)
This study aimed to compare survival outcomes and clinical characteristics between ER loss and metastatic triple-negative breast cancer (mTNBC) patients, exploring the prognostic implications of dynamic ER changes.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 197 (actual)
- First submitted
- 19 Dec 2025
- Start date
- 31 Dec 2024
- Primary completion date
- 5 Jun 2025
- Lead sponsor
- Fudan University
- NCT number
- NCT07316439
What you commit to
- Study type: Observational
- Participants enrolled: 197
- From 31 Dec 2024 to the primary completion date, 5 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with incomplete medical records and those diagnosed with secondary primary tumors
Who the study is looking for
- Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage.
- MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2017 and 2023
- Patients diagnosed with primary ER-positive tumor and who were yet to receive any systemic therapy during the advanced stage
- Contemporaneous patients with metastatic TNBC at initial diagnosis
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.